Sign in Subscribe

article

A collection of 642 issues

Stage III/IV MSI-H CRC Shows Reduced T-Cell Infiltration and Elevated IDO1

Skip to content The CRC Digest Stage III/IV MSI-H CRC Shows Reduced T-Cell Infiltration and Elevated IDO1 Analysis of 217 patients with dMMR/MSI-H colorectal cancer found that stage III/IV tumors had reduced immune infiltration and upregulated epithelial IDO1 expression compared to stage I/II, suggesting immune evasion

Sotorasib Plus Panitumumab Produces Response in Rare NRAS G12C-Mutated MSI-H Rectal Cancer

Skip to content The CRC Digest Sotorasib Plus Panitumumab Produces Response in Rare NRAS G12C-Mutated MSI-H Rectal Cancer A case report describes an objective tumor response to the KRAS G12C inhibitor sotorasib combined with EGFR blockade in a patient with advanced NRAS G12C-mutated, mismatch repair-deficient rectal adenocarcinoma refractory to immunotherapy.

CRC Research Finding

Skip to content The CRC Digest ▸ Meta-Analysis Compares TAS-102 and Regorafenib Sequencing in Later-Line mCRC A systematic review and meta-analysis compared efficacy and safety of TAS-102 followed by regorafenib versus the reverse sequence in patients with metastatic colorectal cancer who had previously failed chemotherapy. (Chin Clin Oncol) This content is

Microbiota influences immunotherapy efficacy in MSI-H colorectal cancer

Skip to content The CRC Digest Microbiota influences immunotherapy efficacy in MSI-H colorectal cancer Immune checkpoint inhibitors benefit patients with mismatch repair-deficient/microsatellite instability-high colorectal cancer, and gut microbiota appears to play a key role in treatment response. (Life Sciences) This content is informational only and does not constitute medical

KRAS G12C inhibitor Krazati fails confirmatory phase 3 trial

Skip to content The CRC Digest KRAS G12C inhibitor Krazati fails confirmatory phase 3 trial The Krystal-10 study did not meet primary endpoints in 461 patients with KRAS G12C-mutated metastatic colorectal cancer, raising questions about the drug's path to full FDA approval. (Fierce Pharma) This content is informational

Colonoscopy trends and disparities in early-onset CRC examined across multiple states

Skip to content The CRC Digest Colonoscopy trends and disparities in early-onset CRC examined across multiple states Researchers analyzed 1,388 early-onset colorectal cancer patients to understand whether rising disease burden reflects increased screening or a true epidemiologic shift, with focus on racial and ethnic differences. (Surgery) This content is

CRC Research Finding

Skip to content The CRC Digest ◇ Review highlights gut microbiota's role in immunotherapy response, especially for MSI-H tumors A comprehensive review evaluates how gut microbiota and microbial metabolites influence colorectal cancer development, the tumor microenvironment, and immunotherapy responses, with emphasis on strategies for proficient mismatch repair/microsatellite-stable tumors

Review examines liquid biopsy potential and limitations for CRC screening

Skip to content The CRC Digest Review examines liquid biopsy potential and limitations for CRC screening Analysis notes promise of circulating tumor DNA and cells for detection but highlights limited sensitivity for advanced adenomas and lack of randomized trial evidence for mortality reduction. (Intestinal Research) This content is informational only

New blood test achieves 60% sensitivity for early-stage cancers

Skip to content The CRC Digest New blood test achieves 60% sensitivity for early-stage cancers Caris Detect combines whole genome sequencing and AI; ACHIEVE 1 study showed 60.3% sensitivity for stage I-II cancers including colorectal. (Fierce Biotech) This content is informational only and does not constitute medical advice. Always

BREAKWATER explores molecular markers in BRAF V600E disease

Skip to content The CRC Digest BREAKWATER explores molecular markers in BRAF V600E disease Phase III trial data from ESMO GI examines correlates of response to encorafenib plus cetuximab and chemo. (Oncodaily) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team.